Table 4.

EQ-5D-3L-derived health utilities for major adverse cardiovascular events

	Rivaroxaban plus aspirin	Aspirin alone	Total
Stroke
n, with EQ-5D available within 3 months after the event	31	53	84
Mean (SD)	0.744 (0.209)	0.712 (0.276)	0.724 (0.253)
Median (Q1, Q3)	0.794 (0.689, 0.849)	0.810 (0.597, 0.854)	0.800 (0.597, 0.854)
P value*	0.948
Myocardial infarction
n, with EQ-5D available within 3 months after the event	67	80	147
Mean (SD)	0.816 (0.185)	0.831 (0.182)	0.825 (0.183)
Median (Q1, Q3)	0.827 (0.761, 1.000)	0.844 (0.778, 1.000)	0.843 (0.770, 1.000)
P value*	0.609
Heart failure
n, with EQ-5D available within 3 months after the event	77	98	175
Mean (SD)	0.764 (0.220)	0.756 (0.21)	0.760 (0.214)
Median (Q1, Q3)	0.808 (0.708, 0.860)	0.810 (0.721, 0.844)	0.810 (0.708, 0.854)
P value*	0.995
Venous thromboembolism
n, with EQ-5D available within 3 months after the event	5	16	21
Mean (SD)	0.839 (0.150)	0.757 (0.175)	0.777 (0.169)
Median (Q1, Q3)	0.778 (0.708, 1.000)	0.810 (0.703, 0.827)	0.810 (0.708, 0.827)
P value*	0.617
Major bleeding
n, with EQ-5D available within 3 months after the event	135	73	208
Mean (SD)	0.817 (0.185)	0.836 (0.154)	0.824 (0.175)
Median (Q1, Q3)	0.827 (0.778, 1.000)	0.827 (0.781, 1.000)	0.827 (0.778, 1.000)
P value*	0.944

SD, standard deviation.

^*Mann–Whitney U test.